| Objective To investigate soluble CD86's role in the pathogenesis of asthma we observed serum soluble CD86,IL-4,IFN-γlevels in patients with chronic persistent allergic asthma and healthy persons,and examined the changes of serum sCD86,IL-4,IFN-γlevels in the asthmatic patients inhaled salmeterol and fluticasone propionate powder.Methods Asthmatic group which include 23 chronic asthmatic patients inhaled salmeterol and fluticasone propionate powder for a month were detected serum sCD86, IFN-γ,IL-4 (using enzyme-linked immune assay) , peripheral blood eosinophils counts and their lung functions at the 0th ,7 th and 31th day respectively, then compared with each other;and take asthma control test before treatment and 1 month for treatment respectively,then compared with each other. normal group which include 12 healthy volunteers just measured peripheral blood eosinophils counts, serum sCD86, IFN-γ,IL-4 and compared with the asthmatic group.Result (1)The levels of serum sCD86 in asthmatic group were significantly higher than normal group before treatment (565.71±25.69IU/ml vs458.52±21.97 IU/ml, P<0.05),then it were decreased after 1 week's treatment and 1 month's treatment respectively(489.29±20.26IU/ml vs befor treatment P<0.05;459.12±20.79 IU/ml vs befor treatment P<0.01) which were no significant difference with the normal group (P>0.05). (2)Serum IL-4 levels in asthmatic patients higher than the normal group's level before treatment (139.45±5.52ng/L vs 78.70±4.75ng/L,P <0.01),then it droped after treatment for 1 week which were still higher than normal group's level (111.35±5.63ng/L,P <0.01), after treatment of 1 month IL-4 levels droped to the normal range(89.94±4.82 ng/L,P> 0.05). Serum IFN-γlevels in asthmatic patients were lower than the normal group's level before treatment (6.58±1.80ng/L vs47.19±5.87ng/L,P<0.01),and its increased after treatment for 1 week which still lower than normal group's level (24.96±4.13ng/L,P <0.01),after treatment of 1 month IFN-γin asthmatic patients increased to the normal range (49.26±5.08 ng/L,P> 0.05).(3)The eosinophil counts in asthmatic patients were higher than the normal group before treatment (0.63±0.09*109/L vs 0.27±0.03*109/L,P <0.01),then it droped after treatment for 1 week and for 1 month which were no significant difference with the normal group (0.48±0.06*109/L,0.34±0.04*109/L,P>0.05).(4)The FEV1%pred and PEF%pred in asthmatic patients rised continuously with 1 week's treatment and 1 month's treatment (df=2, F=18.20,P=0.00;dfε=1.57,F=20.70,P=0.00).ACT score in asthmatic patients increased after treatment(P<0.01).(5)Partial correlation analysis showed there was positive correlation between sCD86 and IL-4 levels or EOS counts(rsCD86 IL-4,IFN-γEOS=0.26,P=0.03;rsCD86 EOS,IFN-γIL-4=0.46,P=0.00),and there was positive correlation between EOS counts and IL-4 levels(rEOS IL-4,IFN-γ=0.32,P=0.01),and there was no significant correlation between sCD86 and IFN-γ, FEV1% pred, PEF% pred. Univariate correlation analysis showed there was a significant negative correlation between serum sCD86 levels and ACT score(r=-0.737,P=0.000).Conclusion The peripheral blood serum sCD86 levels and eosinophils counts in patients with chronic persistent allergic asthma were significantly increased, And there were IL-4/IFN-γcytokine imbalance in asthmatic patients;After salmeterol fluticasone propionate inhalation serum sCD86 levels and eosinophils counts were significantly reduced, and IL-4/IFN-γcytokine imbalance was corrected. There was closely relationship between sCD86 levels and EOS counts, IL-4 levels in patients with chronic persistent allergic asthma, suggesting that sCD86 may be involved in the pathogenesis of asthma. |
PDF Full Text Request